logo
Young Veteran Amputees Have Higher Hip Osteoarthritis Risk

Young Veteran Amputees Have Higher Hip Osteoarthritis Risk

Medscape15-05-2025

INCHEON, South Korea — Young veterans who have lost lower limbs in combat are at particularly high risk for developing hip osteoarthritis, but even uninjured veterans of similar age and service history also have elevated risk for the disease, according to research presented at the World Congress on Osteoarthritis (OARSI) 2025 Annual Meeting.
Fraje Watson, PhD, research associate in bioengineering at Imperial College London, London, England, presented an analysis of data from the ongoing prospective longitudinal ADVANCE cohort study in UK military personnel who served in Afghanistan.
The analysis involved 1141 participants who had hip x-rays available at the study baseline, which was a mean of 8 years after injury or deployment. Around half of the participants had experienced severe enough injury during combat to require aeromedical evacuation, while the other half were a control group of military personnel who had not required aeromedical evacuation for injury and were matched for age, time and duration of deployment, and role.
Of the 577 veterans exposed to serious injury, 142 had experienced one or both lower limb amputations, 28 had experienced hip injury (with or without lower limb loss), and 407 did not experience any limb loss.
The study found that at baseline, just over 14% of veterans who had lower limb loss had hip osteoarthritis of Kellgren and Lawrence grade ≥ 2 compared with 4.4% of the control group who did not experience serious injury requiring aeromedical evacuation, representing a 3.88-fold higher likelihood of developing hip osteoarthritis. Among those who experienced serious hip injury with or without limb loss, 28.6% met the criteria for hip osteoarthritis at baseline, representing 7.18-fold higher odds of developing hip osteoarthritis than those in the control group.
At the 3-year follow-up from baseline, the study didn't find any significantly greater increases in overall incidence of new hip osteoarthritis in the exposed groups compared with controls. But they did see significant differences in the risk for progression to more severe disease: 38.5% of the individuals who had experienced hip injury and 24.3% of those who experienced lower limb loss had progressed compared with 17% without limb loss and 14.1% of those who did not experience severe injury.
Fraje Watson, PhD
'General trauma doesn't appear to increase the risk, but hip injuries and lower limb loss do, and they also result in an increased risk of progression over time, within 8-11 years post-injury,' Watson told the conference. She suggested that the effect could be the result of altered gait biomechanics and increased contact forces on the contralateral limb, although the cohort also included individuals who had lost both limbs.
Watson also drew attention to the relatively high rate of hip osteoarthritis at baseline and follow-up even among the military veterans who had not experienced serious injury. The mean age of participants was around 34 years, and nearly two thirds were of junior rank.
'For such a young group that's much less reported in the literature, they had quite a high baseline prevalence,' Watson told the conference. 'Even if we take out the injured group and we just look at the group that served in Afghanistan but didn't experience a significant injury, they still had a 4.4% baseline prevalence.' In comparison to this, reports suggested a prevalence of 1.4% among men younger than 40 years in the general population, she said.
Watson commented to Medscape Medical News that the higher rate of hip osteoarthritis among military personnel may reflect the physical demands of military service. 'They have a really high level of activity, and the loading of their joints is potentially higher for a sustained period of time as well as being extremely active,' she said. 'They might also be slightly more at higher risk of sustaining those kinds of low-level twisted ankles or meniscal injuries during training.'
An audience member asked whether the study was looking at the sacroiliac joints and low back pain in these patients, given their mechanical axis and weight-bearing might also shift with the loss of a limb.
Watson noted that a paper currently under review was examining low back pain in individuals with lower limb loss, and that there were a number of mechanical changes that happen around both the hip and lower back with limb loss.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Women on blockbuster weight loss drugs warned to use effective contraception
Women on blockbuster weight loss drugs warned to use effective contraception

Yahoo

time3 days ago

  • Yahoo

Women on blockbuster weight loss drugs warned to use effective contraception

Pregnant women should not take weight loss drugs, the UK's medicines regulator warned amid concerns that people are using the so-called 'skinny jabs' in unsafe ways. The UK Medicines and Healthcare products Regulatory Agency (MHRA) also said women should not take weight loss drugs if they are breastfeeding or trying to get pregnant, because there isn't enough safety data to know whether the medicine could affect their baby. 'Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible,' the agency said. Meanwhile, all women taking the jabs should ensure they are using a form of contraception that works, the MHRA said. Related Weight-loss drugs like Wegovy could help serious liver condition that has no cure-all treatment One of the drugs, Mounjaro, may make birth control pills less effective, so the agency says women taking the jab should also use a non-oral form of contraception, like an implant or intrauterine device (IUD). 'Obesity reduces fertility in women. So, women with obesity taking GLP-1 drugs are more likely to get pregnant than before they lost weight,' Dr Channa Jayasena, a reproductive endocrinology researcher at Imperial College London, said in a statement. 'Women are advised to do all they can to prevent pregnancy while taking [these] drugs,' Jayasena added. Related France won't pay for weight loss drug Wegovy. What about other European countries? In the UK, women already receive these warnings when they get their prescriptions for the blockbuster jabs, which include Ozempic, Wegovy, Saxenda, and Victoza as well as Mounjaro. The drugs, known as GLP-1 receptor agonists, work by mimicking hormones that help regulate appetites and make people feel full for longer. They have been approved to treat type 2 diabetes and obesity. Related Why are 1 in 10 French women still smoking during pregnancy despite the health risks? But the MHRA issued the reminder Thursday due to concerns that the drugs' growing popularity means women are buying them illegally online or at beauty salons, without seeing a doctor. 'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments,' Dr Alison Cave, MHRA's chief safety officer, said in a statement. 'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way,' she added.

Women on blockbuster weight loss drugs warned to use effective contraception
Women on blockbuster weight loss drugs warned to use effective contraception

Yahoo

time4 days ago

  • Yahoo

Women on blockbuster weight loss drugs warned to use effective contraception

Pregnant women should not take weight loss drugs, the UK's medicines regulator warned amid concerns that people are using the so-called 'skinny jabs' in unsafe ways. The UK Medicines and Healthcare products Regulatory Agency (MHRA) also said women should not take weight loss drugs if they are breastfeeding or trying to get pregnant, because there isn't enough safety data to know whether the medicine could affect their baby. 'Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible,' the agency said. Meanwhile, all women taking the jabs should ensure they are using a form of contraception that works, the MHRA said. Related Weight-loss drugs like Wegovy could help serious liver condition that has no cure-all treatment One of the drugs, Mounjaro, may make birth control pills less effective, so the agency says women taking the jab should also use a non-oral form of contraception, like an implant or intrauterine device (IUD). 'Obesity reduces fertility in women. So, women with obesity taking GLP-1 drugs are more likely to get pregnant than before they lost weight,' Dr Channa Jayasena, a reproductive endocrinology researcher at Imperial College London, said in a statement. 'Women are advised to do all they can to prevent pregnancy while taking [these] drugs,' Jayasena added. Related France won't pay for weight loss drug Wegovy. What about other European countries? In the UK, women already receive these warnings when they get their prescriptions for the blockbuster jabs, which include Ozempic, Wegovy, Saxenda, and Victoza as well as Mounjaro. The drugs, known as GLP-1 receptor agonists, work by mimicking hormones that help regulate appetites and make people feel full for longer. They have been approved to treat type 2 diabetes and obesity. Related Why are 1 in 10 French women still smoking during pregnancy despite the health risks? But the MHRA issued the reminder Thursday due to concerns that the drugs' growing popularity means women are buying them illegally online or at beauty salons, without seeing a doctor. 'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments,' Dr Alison Cave, MHRA's chief safety officer, said in a statement. 'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way,' she added.

Diabetes Status May Not Affect Outcomes of Preventive PCI
Diabetes Status May Not Affect Outcomes of Preventive PCI

Medscape

time4 days ago

  • Medscape

Diabetes Status May Not Affect Outcomes of Preventive PCI

The PREVENT trial found preventive percutaneous coronary intervention (PCI) combined with optimal medical therapy was more effective than medical therapy alone in reducing major adverse cardiac events in patients with non–flow-limiting vulnerable plaques. The new analysis found patients with non–flow-limiting vulnerable plaques had similar 2-year cardiac outcomes regardless of diabetes status, but those who received preventive PCI combined with optimal medical therapy had lower rates of cardiac events than those who received medical therapy alone. METHODOLOGY: The post hoc analysis of the PREVENT data compared the clinical outcomes of preventive PCI plus optimal medical therapy and medical therapy alone in patients with (n = 490) or without (n = 1116) diabetes. Plaques were defined as non–flow-limiting when the fractional flow reserve was > 0.80; vulnerable plaques were identified using intracoronary imaging. The primary endpoint was a composite of cardiac death, target vessel myocardial infarction, ischemia-driven target vessel revascularization, or hospitalization for unstable or progressive angina at 2 years after randomization; the median follow-up duration was 4.3 years. TAKEAWAY: At 2 years, the incidence of the composite primary endpoint was not significantly different between patients with diabetes and those without the condition (1.8% and 1.9%, respectively; P = .956). = .956). The composite primary endpoint occurred less frequently with preventive PCI than with optimal medical therapy alone for both patients with diabetes (0% vs 3.7%; log-rank P = .003) and those without diabetes (0.5% vs 3.2%; log-rank P < .001). = .003) and those without diabetes (0.5% vs 3.2%; log-rank < .001). The reduced incidence of the primary endpoint with preventive PCI was mainly driven by reduced rates of ischemia-driven target vessel revascularization and hospitalizations for unstable or progressive angina in both patients with diabetes and those without the disorder. IN PRACTICE: 'These findings support that preventive PCI…irrespective of diabetes status, in patients with non–flow-limiting vulnerable coronary plaques,' the researchers wrote. Vulnerable plaques 'may be guilty by association but may not be the sole culprit behind residual cardiovascular risk,' wrote Diana A. Gorog, MD, PhD, of Imperial College London, London, England, in an editorial accompanying the journal article. Such plaques 'may be just one marker of a vulnerable patient, but not the only determinant of risk. Perhaps we need to find better ways of identifying the vulnerable patient, rather than focusing solely on vulnerable plaques,' Gorog added. SOURCE: This study was led by Min Chul Kim of Chonnam National University Hospital in Gwangju, South Korea. It was originally presented at American College of Cardiology (ACC) Scientific Session 2024 and was published online on May 29, 2025, in European Heart Journal . LIMITATIONS: The clinical outcomes were exploratory as the study was powered only for the composite primary endpoint, with event rates lower than anticipated. The researchers did not differentiate between type 1 and type 2 diabetes, which might have limited the generalizability of the findings. Intravascular imaging at follow-up was not performed routinely. DISCLOSURES: This study was funded by the CardioVascular Research Foundation, Abbott, Yuhan Corp, CAH-Cordis, Philips, and Infraredx. Several authors reported receiving research grants, consulting fees, and honoraria from various pharmaceutical and healthcare companies, including the funding agencies.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store